Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Part of paid clinical trials in Columbia, Missouri.

Sponsor
VA Office of Research and Development
Study ID
NCT06745063
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Empagliflozin — DRUG
    12 week treatment with 10mg empagliflozin daily
  • Placebo — DRUG
    12 week treatment with 10mg placebo daily

Study Details

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Key Dates

Start date
May 30, 2025
Status verified
Nov 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    12 week treatment with 10mg empagliflozin daily
  • Placebo Comparator: Placebo
    12 week treatment with 10mg placebo daily

Primary Outcome Measure

Carotid-femoral Pulse Wave Velocity (cfPWV) [ Time Frame: baseline (t0), week 4, week 8, week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Harry S. Truman Memorial, Columbia, MOColumbiaMissouri65201-5275
Jaume Padilla Parellada, PhD
[email protected]
573-814-6552
Jaume Padilla Parellada, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Columbia, MO

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Harry S. Truman Memorial, Columbia, MO· Columbia, MO

Related Studies